Profitability Ratios
| Ratio |
Value |
| GP Margin |
97.9% |
| EBIT Margin |
-7.9% |
| EBITDA Margin |
4.5% |
| Operating Margin |
-12.8% |
| Pretax Margin |
-10.0% |
| Cont. Ops Margin |
-10.2% |
| Net Margin |
-5.2% |
| Bottom Line Margin |
-5.2% |
Liquidity Ratios
| Ratio |
Value |
| Current Ratio |
2.74 |
| Quick Ratio |
2.70 |
| Solvency Ratio |
0.072 |
| Cash Ratio |
0.58 |
Valuation Ratios
| Ratio |
Value |
| Price/Earnings |
|
| PEG Ratio |
0.79 |
| Forward PEG |
0.79 |
| Price/Book |
29.69 |
| Price/Sales |
6.95 |
| Price/FCF |
-167.32 |
| Price/Op Cash Flow |
90.22 |
Debt Ratios
| Ratio |
Value |
| Debt/Assets |
0.5432 |
| Debt/Equity |
2.8628 |
| Debt/Capital |
0.7411 |
| Long-Term Debt/Capital |
0.7308 |
| Financial Leverage |
5.27 |
Cash Flow Ratios
| Ratio |
Value |
| Working Capital Turnover |
1.99 |
| Operating Cash Flow Ratio |
0.236 |
| Operating Cash Flow/Sales |
7.7% |
| Free Cash Flow/Operating Cash Flow |
-53.9% |
Coverage Ratios
| Ratio |
Value |
| Debt Service Coverage |
1.98 |
| Interest Coverage |
-5.8452 |
| Short-Term Operating Cash Flow Coverage |
0.00 |
| Operating Cash Flow Coverage |
0.11 |
| Capital Expenditure Coverage |
0.65 |
| Dividend + Capital Expenditure Coverage |
0.65 |
Dividend Ratios
| Ratio |
Value |
| Payout Ratio |
0.0000% |
| Dividend Yield |
0.0000% |
| Dividend Yield % |
0.0000% |
| Dividend Per Share |
0.0000 |
Per Share Ratios
| Ratio |
Value |
| Revenue/Share |
5.50 |
| EPS |
-0.286 |
| Debt/Share |
3.8053 |
| Cash/Share |
3.62 |
| Book Value/Share |
1.29 |
| Tangible BV/Share |
0.02 |
| Equity/Share |
1.29 |
| Operating Cash Flow/Share |
0.424 |
| Capital Expenditure/Share |
0.652 |
| FCF/Share |
-0.228 |
Other Ratios
| Ratio |
Value |
| Net Income/Earnings Before Tax |
0.518 |
| Earnings Before Tax/EBIT |
0.784 |
| Price/Fair Value |
29.69 |
| Debt/Market Cap |
0.0914 |
| Effective Tax Rate |
-2.0% |
| Enterprise Value Multiple |
164.03 |
TVTX - Travere Therapeutics, Inc.